Shkreli's Empire Collapses: KaloBios Seeks Bankruptcy Protection
This article was originally published in Scrip
In just a few short weeks, Martin Shkreli's empire has collapsed.
You may also be interested in...
Daraprim, which saw its price jacked up by 4,000% by former drug company executive Martin Shkreli, now has a competitor with the US Food and Drug Administration’s approval of the first generic version of the nearly seven-decade-old drug used to treat a life-threatening parasitic infection known as toxoplasmosis.
US FDA approved its first treatment for the tropical disease and awarded a priority review voucher that will be sold as per agreement between development partners.
House bill that would require new clinical studies from sponsor for tropical disease priority review vouchers met with industry concerns about limiting the US agency's flexibility.